Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
58
resultados
Última actualización
13/08/2025 [07:43:00]
Resultados 25 a 50 de 58
Resumen de: MX2024013690A
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: CN119866443A
Described herein are methods for detecting conformational diseases, aging, and proteinopathies by measuring the presence of b-isox precipitates and the level of b-isox capture proteins in biological fluids of healthy individuals and patients. The studies have identified additional biomarkers that make it possible to detect biomarkers by adding or not adding isoxazole to the obtained biological fluid sample, thereby making it possible to detect, diagnose or treat human diseases in a human subject. Diagnosis of disease using b-isox and/or biomarkers becomes possible.
Resumen de: US2024360206A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: US2025224408A1
Provided herein are methods, compositions, and systems for diagnosing, assessing the likelihood of Alzheimer's disease, and assessing the rate of progression of Alzheimer's disease comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers. Also provided herein are methods of assessing the likelihood of dementia progression or the rate of dementia progression comprising assaying biofluid samples and identifying from the biofluid samples the presence/abundance of one or more biomarkers.
Resumen de: US2025222034A1
A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative/healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.
Resumen de: EP4582144A2
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
Resumen de: WO2025138512A1
Provided are an apolipoprotein E detection reagent and the use thereof. The reagent comprises at least one of an ApoE2 protein detection reagent, an ApoE3 protein detection reagent and an ApoE4 protein detection reagent. One of a capture antibody and a detection antibody used for detecting ApoE2 protein or ApoE4 protein is a specific monoclonal antibody, and the capture antibody and the detection antibody used for detecting ApoE3 are both specific monoclonal antibodies. Genotyping of ApoE and quantitative detection of different genotypes of proteins are performed on the basis of an immunological detection method. The detection method has the advantages of being simple, easy to operate, short in time and cheap. A genotype detection result is highly consistent with a fluorescence PCR result. Genotyping of ApoE (6 types) can be performed, which is used to replace the nucleic acid detection and guide medication, and clarify the correlation of the ApoE4 genotype homozygosity/heterozygosity and the protein concentration of ApoE4 with AD.
Resumen de: US2025215504A1
The present invention includes a method for analyzing tRNAHisGTG fragments. In one aspect, the present invention includes a method of identifying a subject in need of therapeutic intervention to treat and/or prevent a disease or condition, disease recurrence, or disease progression comprises characterizing the identity of tRNAHisGTG fragments. The invention further includes diagnosing, identifying or monitoring a disease or condition, a panel of engineered oligonucleotides, a kit for a high-throughput assay, and a method and system for identifying tRNAHisGTG fragments.
Resumen de: WO2024042210A1
The invention relates to methods and uses of cell free histone H3 isoforms H3.1, H3.2, H3t and/or H3.3 (or cell free nucleosomes containing said isoforms) of determining the origin of a cell free histone or cell free nucleosome in a body fluid sample as originating from a dividing or non-dividing cell.
Resumen de: AU2023329158A1
The invention relates to methods of detecting, diagnosing or monitoring an inflammatory condition of the central nervous system, in particular by detecting or measuring neutrophil extracellular traps, extracellular traps and/or cell free nucleosomes.
Resumen de: EP4578872A1
Provided is an anti-TREM2 single-domain antibody, consisting of heavy chains comprising CDR1 represented by any one of SEQ ID NOs: 34-40, CDR2 represented by any one of SEQ ID NOs: 41-45, and CDR3 represented by any one of SEQ ID NOs: 46-50. The single-domain antibody has good affinity with TREM2.
Resumen de: CN119744269A
Provided herein are antibodies or fragments thereof that specifically bind to the microtubule binding region (MTBR) of tau, and uses thereof. Further provided are methods of detecting MTBR species in blood or cerebrospinal fluid, as well as the use of such detection for diagnosing, prognosing or staging pathological characteristics and/or clinical symptoms of tauopathy, and selecting a treatment suitable for a given disease stage.
Resumen de: AU2025204068A1
Abstract Provided herein are sulfopropanoic acid derivatives or pharmaceutically acceptable salts thereof, for treating a disease characterized by amyloid and amyloid-like aggregates, e.g., Alzheimer's disease.
Resumen de: US2025208143A1
Disclosed are fragments of p53 peptide (P1) and their use in the diagnosis and/or prognosis of Alzheimer's disease (AD) in a biological sample. The invention provides a method based on mass spectrometry analysis for the diagnosis of Alzheimer's disease at the pre-clinical and prodromal stages of the disease and for the prognosis of cognitive decline in a subject, by quantitating the levels of one or more p53 peptide fragments in a biological sample of a subject.
Resumen de: US2025208135A1
The present invention provides a method for early detection or diagnosis of a neurodegenerative disease, disorder, or condition in a subject at risk of developing or suspected of having the neurodegenerative disease, disorder, or condition, the method comprising measuring in a blood sample obtained from the subject or a fraction thereof the levels of at least one biomarker selected from CD38+ peripheral blood mononuclear cells (PBMCs), trigonelline, GLUT1 expression in CD4+ T cells, Th2, Th2/Th1 ratio, naïve T cells, adenosine, allose, and HLA-DR T cells, as well as related methods and kits.
Resumen de: WO2025137532A1
Disclosed herein are methods of measuring amyloid β protofibril levels in biological samples. Methods disclosed herein may detect amyloid β protofibril at femtomolar concentrations and selectively measure protofibril as compared to amyloid β monomers.
Resumen de: WO2025137359A1
Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: KR20250094348A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 갈렉틴-7(Galectin-7) 단백질의 발현 수준이 11배 높게 나타나는 것을 확인함에 따라 갈렉틴-7(Galectin-7) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094345A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 판테테이나제(Pantetheinase) 단백질의 발현 수준이 48배 높게 나타나는 것을 확인함에 따라 판테테이나제(Pantetheinase) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094347A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 BCAM(Basal cell adhesion molecule) 단백질의 발현 수준이 13배 높게 나타나는 것을 확인함에 따라 BCAM(Basal cell adhesion molecule) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094346A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 Rab2A(Ras-related protein Rab-2A) 단백질의 발현 수준이 15배 높게 나타나는 것을 확인함에 따라 Rab2A(Ras-related protein Rab-2A) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094349A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 TMEM266(Transmembrane protein 266) 단백질의 발현 수준이 11배 높게 나타나는 것을 확인함에 따라 TMEM266(Transmembrane protein 266) 단백질 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Resumen de: KR20250094344A
본 발명은 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환을 진단할 수 있는 새로운 엑소좀 유래 바이오마커를 제공하는 것으로, MRI 영상 기반으로 뇌 국소영역을 정밀하게 구분하여 해당 국소 영역에서만 혈뇌장벽의 변성된 동물 모델을 제작하고, BBB 손상 동물 모델에서 분리된 혈청(serum)으로부터 엑소좀 단백질의 발현 수준을 비교 분석하여, BBB 손상 동물 모델에서 호르네린(Hornerin) 단백질의 발현 수준이 98배 높게 나타나는 것을 확인함에 따라 호르네린(Hornerin) 또는 이의 mRNA를 혈뇌장벽(blood-brain barrier)의 손상으로 인한 뇌질환의 진단용 바이오마커로 제공한다.
Nº publicación: JP2025094219A 24/06/2025
Solicitante:
エイシーイミューンソシエテアノニム
Resumen de: PH12021552938A1
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
BOPI
Sede Electrónica
